Unveiling the Antibacterial Properties of Statins: An Study on

Overview

Journal Adv Pharmacol Pharm Sci

Publisher Wiley

Date 2024 Aug 20

PMID 39161645

Authors

Manijeh Ebrahimzadeh

Fariba Asgharpour

Javad Shokri Shirvani

Sohrab Kazemi

Ali Akbar Moghadamnia

Affiliations

Soon will be listed here.

Abstract

Background: (), a widespread bacterial pathogen, is associated with various gastrointestinal diseases, including gastric cancer. Statins, widely prescribed cholesterol-lowering agents, have demonstrated pleiotropic effects, including potential antimicrobial properties. This study investigated the direct antibacterial effects of three clinically approved statins, simvastatin, atorvastatin, and rosuvastatin, against isolates.

Methods: strains were isolated from gastric biopsies of dyspeptic patients and identified by microbiological techniques. The minimum inhibitory concentrations (MICs) of statins were determined using the agar dilution method, and their antimicrobial activity was evaluated by the disc diffusion method using different concentrations of simvastatin, atorvastatin, rosuvastatin, tetracycline, and amoxicillin. Scanning electron microscopy (SEM) was employed to examine the morphology of cells.

Results: The minimum inhibitory concentration (MIC) values (g/mL) of atorvastatin, rosuvastatin, simvastatin, tetracycline, and amoxicillin against were 240 ± 20, 450 ± 20, 460 ± 15, 155 ± 30, and 140 ± 20, respectively. In the disc diffusion assay, atorvastatin and rosuvastatin produced significantly larger inhibition zones compared to simvastatin at all concentrations tested ( < 0.05). The inhibition zone diameters (mm) increased with higher statin concentrations, ranging from 9 ± 1.4 to 13 ± 1.4 for atorvastatin, 8 ± 0.9 to 11 ± 0.6 for rosuvastatin, and 5 ± 1.3 to 6 ± 1.4 for simvastatin at the highest tested concentration (1200 g/ml). SEM analysis revealed the characteristic spiral morphology of cells.

Conclusion: Statins demonstrated varying degrees of antibacterial activity against isolates, with atorvastatin exhibiting the highest potency. While the observed effects were lower than those of conventional antibiotics, these findings suggest the potential of statins as adjunctive agents or alternative therapeutic options, warranting further investigation through studies and clinical trials.

References

Abdullahi M, Annibale B, Capoccia D, Tari R, Lahner E, Osborn J . The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg. 2008; 18(11):1450-4. DOI: 10.1007/s11695-008-9477-z. View

Muck A, Seeger H, Wallwiener D . Class-specific pro-apoptotic effect of statins on human vascular endothelial cells. Z Kardiol. 2004; 93(5):398-402. DOI: 10.1007/s00392-004-0081-5. View

Young K, Allaker R, Hardie J . Morphological analysis of Helicobacter pylori from gastric biopsies and dental plaque by scanning electron microscopy. Oral Microbiol Immunol. 2001; 16(3):178-81. DOI: 10.1034/j.1399-302x.2001.016003178.x. View

Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M . Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004; 110(7):880-5. DOI: 10.1161/01.CIR.0000138932.17956.F1. View

Franceschi F, Covino M, Baudron C . Review: Helicobacter pylori and extragastric diseases. Helicobacter. 2019; 24 Suppl 1:e12636. DOI: 10.1111/hel.12636. View

Taylor F, Huffman M, Ebrahim S . Statin therapy for primary prevention of cardiovascular disease. JAMA. 2013; 310(22):2451-2. DOI: 10.1001/jama.2013.281348. View

Sarkeshikian S, Ghadir M, Alemi F, Jalali S, Hormati A, Mohammadbeigi A . Atorvastatin in combination with conventional antimicrobial treatment of Helicobacter pylori eradication: A randomized controlled clinical trial. J Gastroenterol Hepatol. 2019; 35(1):71-75. DOI: 10.1111/jgh.14810. View

Welsh A, Kruger P, Faoagali J . Antimicrobial action of atorvastatin and rosuvastatin. Pathology. 2009; 41(7):689-91. DOI: 10.3109/00313020903305860. View

Gehring S, Tapia-Perez J, Kirches E, Firsching R, Keilhoff G, Schneider T . Cytotoxic effects of statins and thiazolidinediones on meningioma cells. J Neurooncol. 2010; 102(3):383-93. DOI: 10.1007/s11060-010-0351-1. View

10.

Motzkus-Feagans C, Pakyz A, Polk R, Gambassi G, Lapane K . Statin use and the risk of Clostridium difficile in academic medical centres. Gut. 2012; 61(11):1538-42. PMC: 3405173. DOI: 10.1136/gutjnl-2011-301378. View

11.

Graziano T, Claudia Cuzzullin M, Franco G, Schwartz-Filho H, de Andrade E, Groppo F . Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus Biofilm. PLoS One. 2015; 10(5):e0128098. PMC: 4447369. DOI: 10.1371/journal.pone.0128098. View

12.

Yang H, Guan L, Hu B . Detection and Treatment of : Problems and Advances. Gastroenterol Res Pract. 2022; 2022:4710964. PMC: 9617708. DOI: 10.1155/2022/4710964. View

13.

Kuo C, Lee C, Chang M, Lin C, Lin W, Su M . Multidrug resistance: The clinical dilemma of refractory Helicobacter pylori infection. J Microbiol Immunol Infect. 2021; 54(6):1184-1187. DOI: 10.1016/j.jmii.2021.03.006. View

14.

Nseir W, Diab H, Mahamid M, Abu-Elheja O, Samara M, Abid A . Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. Aliment Pharmacol Ther. 2012; 36(3):231-8. DOI: 10.1111/j.1365-2036.2012.05161.x. View

15.

OToole G, Kolter R . Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol. 1998; 30(2):295-304. DOI: 10.1046/j.1365-2958.1998.01062.x. View

16.

Lin T, Lan W, Chiu Y, Feng C, Chiu C, Kuo C . Statins' Regulation of the Virulence Factors of and the Production of ROS May Inhibit the Development of Gastric Cancer. Antioxidants (Basel). 2021; 10(8). PMC: 8389206. DOI: 10.3390/antiox10081293. View

17.

Khademi F, Poursina F, Hosseini E, Akbari M, Safaei H . Helicobacter pylori in Iran: A systematic review on the antibiotic resistance. Iran J Basic Med Sci. 2015; 18(1):2-7. PMC: 4366738. View

18.

Cai T, Abel L, Langford O, Monaghan G, Aronson J, Stevens R . Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021; 374:n1537. PMC: 8279037. DOI: 10.1136/bmj.n1537. View

19.

White B, Winte M, DeSipio J, Phadtare S . Clinical Factors Implicated in Antibiotic Resistance in Patients. Microorganisms. 2022; 10(2). PMC: 8876575. DOI: 10.3390/microorganisms10020322. View

20.

Hassan A, Shawky M, Mohammed A, Haridy M, Eid K . Simvastatin improves the eradication rate of : upper Egypt experience. Infect Drug Resist. 2019; 12:1529-1534. PMC: 6556530. DOI: 10.2147/IDR.S202346. View